Bioceltix SaGPW: BCX

BCX: Pioneering stem cell therapies for pets, with proven efficacy and major market expansion plans

· Issued by Bioceltix SA

Focuses on allogeneic stem cell therapies for companion animals, with clinical success in canine atopic dermatitis and osteoarthritis. Expanding GMP manufacturing, advancing regulatory submissions, and developing innovative biologics, the company targets a rapidly growing veterinary therapeutics market.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Bioceltix Sa

All Bioceltix Sa news releases